The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer.
Paola C Sacco, Paolo Maione, Cesare Guida...
https://pubmed.ncbi.nlm.nih.gov/27908252/Actively Recruiting
Led by Sun Yat-sen University · Updated on 2025-07-24
497
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating the best timing and combination of treatments for patients with locally advanced non-small cell lung cancer LANSCLC, focusing on neoadjuvant immuno-chemotherapy combined with chemoradiotherapy and consolidative immunotherapy. This phase III randomized controlled trial compares the effectiveness and safety of adding neoadjuvant immuno-chemotherapy before concurrent chemoradiotherapy and consolidative immunotherapy, versus chemoradiotherapy and consolidative immunotherapy alone. The study builds on previous findings from the PACIFIC trial that established immunotherapy after chemoradiotherapy as a standard care, aiming to improve survival outcomes further. Participants are randomly assigned into three groups. Group A receives neoadjuvant chemo-immunotherapy with albumin-bound paclitaxel, cisplatin, and tislelizumab every three weeks, followed by hypofractionated thoracic radiotherapy hypo-RT with concurrent chemotherapy, then consolidative immunotherapy for up to 12 months. Group B undergoes the same neoadjuvant chemo-immunotherapy but with conventionally fractionated thoracic radiotherapy CFRT and concurrent chemotherapy, followed by consolidative immunotherapy for up to 12 months. Group C receives CFRT with concurrent chemotherapy first, then consolidative immunotherapy for up to 12 months. During the trial, participants will have regular assessments including tumor response evaluations, survival tracking, and safety monitoring for adverse events. Quality of life will be measured using specific questionnaires at one year after treatment. Researchers will also monitor eligibility for consolidative immunotherapy following chemoradiotherapy. The primary outcome is progression-free survival at 18 months, with additional follow-ups for overall survival and treatment safety planned over two years. The total participation duration may extend up to several years, including long-term monitoring.
CONDITIONS
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
B
Bo Qiu, Professor
H
Hui Liu, Professor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sun Yat-sen University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Every 3 weeks, duration depends on the number of cycles before radiotherapy
Participants in study groups A and B receive neoadjuvant chemotherapy combined with immunotherapy prior to radiotherapy.
Repeated visits every 3 weeks during neoadjuvant treatment
Duration - Duration varies based on radiotherapy type (hypofractionated or conventional fractionation)
Participants receive thoracic radiotherapy with concurrent chemotherapy. Group A receives hypofractionated radiotherapy; Groups B and C receive conventionally fractionated radiotherapy.
Daily or frequent visits during radiotherapy period
Duration - Up to 12 months starting 1-2 months after chemoradiotherapy
Following chemoradiotherapy, participants receive consolidative immunotherapy with Tislelizumab for up to 12 months, starting 1 to 2 months after chemoradiotherapy.
Regular visits during 12 months of consolidative immunotherapy
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Paola C Sacco, Paolo Maione, Cesare Guida...
https://pubmed.ncbi.nlm.nih.gov/27908252/Scott J Antonia, Augusto Villegas, Davey Daniel...
https://pubmed.ncbi.nlm.nih.gov/28885881/Binbin Wu, Todd McNutt, Marianna Zahurak...
https://pubmed.ncbi.nlm.nih.gov/22867890/Zhongxing X Liao, Ritsuko R Komaki, Howard D Thames...
https://pubmed.ncbi.nlm.nih.gov/19515503/Greg A Durm, Salma K Jabbour, Sandra K Althouse...
https://pubmed.ncbi.nlm.nih.gov/32697352/Maarten J Deenen, Luc Dewit, Henk Boot...
https://pubmed.ncbi.nlm.nih.gov/23517808/Mariano Provencio, Ernest Nadal, Amelia Insa...
https://pubmed.ncbi.nlm.nih.gov/32979984/Patrick M Forde, Jamie E Chaft, Kellie N Smith...
https://pubmed.ncbi.nlm.nih.gov/29658848/Yifan Wang, Weiye Deng, Nan Li...
https://pubmed.ncbi.nlm.nih.gov/29556198/Davide Franceschini, Fabiola Paiar, Icro Meattini...
https://pubmed.ncbi.nlm.nih.gov/23775348/Sun Yat-sen University
Lead Sponsor